直接抑制P70S6K1替代地塞米松与MCL-1抑制剂在多发性骨髓瘤中协同作用
多发性骨髓瘤(MM)耐药和复发仍是主要临床问题,地塞米松等糖皮质激素虽为基石但副作用严重。 lethality screen显示地塞米松与MCL-1抑制剂S63845联合诱导HMCLs凋亡比加性效应高50%。地塞米松降低P70S6K磷酸化50%,用P70S6K1特异性抑制剂PF-4708671替代地塞米松与MCL-1i联用,在9例原代MM样本中均显示超加性凋亡,且对干祖细胞毒性极小。
要点
- 地塞米松联合MCL-1抑制剂S63845在HMCLs中诱导凋亡比加性效应高50%。
- 地塞米松使HMCLs中P70S6K磷酸化降低50%,位于Akt-mTORC1轴下游。
- P70S6K1抑制剂PF-4708671替代地塞米松与MCL-1i联用,在9/9原代MM样本中凋亡超加性。
核心结论
- 直接抑制P70S6K1可替代地塞米松与MCL-1抑制剂协同诱导多发性骨髓瘤细胞凋亡。
- P70S6K特异性抑制可能为不耐受或不敏感于糖皮质激素的患者提供解决方案。
研究设计与样本
- 研究在人类骨髓瘤细胞系(HMCLs)和9例原代MM样本中进行 lethality screen 及联合用药分析。
- 使用地塞米松、MCL-1抑制剂S63845和P70S6K1抑制剂PF-4708671进行联合处理。
主要发现
- 地塞米松与MCL-1i联合诱导HMCLs凋亡比加性效应高50%。
- 地塞米松处理HMCLs后P70S6K磷酸化降低50%,对FOXO蛋白或GSK3无影响。
- P70S6K1i联合MCL-1i在9例原代MM样本中均显示超加性凋亡,而地塞米松联合MCL-1i仅在6/9样本中观察到该效应。
- 联合处理对干祖细胞亚群的毒性极小。
临床怎么用
- P70S6K1抑制剂联合MCL-1抑制剂可作为替代地塞米松的协同方案用于MM治疗。
- 该策略可能适用于不耐受或不敏感于地塞米松等糖皮质激素的MM患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel combination therapies have markedly improved the lifespan of patients with multiple myeloma (MM), but drug resistance and disease relapse remain major clinical problems. Dexamethasone and other glucocorticoids are a cornerstone of conventional and new combination therapies for MM, although their use is accompanied by serious side effects. We aimed to uncover drug combinations that act in synergy and, as such, allow reduced dosing while remaining effective. Dexamethasone and the myeloid cell leukemia 1 (MCL-1) inhibitor S63845 (MCL-1i) proved the most potent combination in our lethality screen and induced apoptosis of human myeloma cell lines (HMCLs) that was 50% higher compared with an additive drug effect. Kinome analysis of dexamethasone-treated HMCLs revealed a reduction in serine/threonine peptide phosphorylation, which was predicted to result from reduced Akt activity. Biochemical techniques showed no dexamethasone-induced effects on FOXO protein or GSK3 but did show a 50% reduction in P70S6K phosphorylation, downstream of the Akt-mTORC1 axis. Replacing dexamethasone by the P70S6K1 isoform-specific inhibitor PF-4708671 (S6K1i) revealed similar and statistically significant synergistic apoptosis of HMCLs in combination with MCL-1i. Interestingly, apoptosis induced by the P70S6K1i and MCL-1i combination was more-than-additive in all 9 primary MM samples tested; this effect was observed for 6 of 9 samples with the dexamethasone and MCL-1i combination. Toxicity on stem and progenitor cell subsets remained minimal. Combined, our results show a strong rationale for combination treatments using the P70S6K inhibitor in MM. Direct and specific inhibition of P70S6K may also provide a solution for patients ineligible or insensitive to dexamethasone or other glucocorticoids.
引用
- Spaan I, Timmerman LM, Kimman T, et al. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma. Blood Adv. 2021. PMID: 34152396. doi:10.1182/bloodadvances.2020003624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。